 VistaGen Therapeutics Inc NASDAQ: VTGN has initiated its PALISADE Phase 3 study to evaluate PH94B for the acute treatment of Social Anxiety Disorder SAD. PH94B is an odorless, rapid-onset, investigational pherine nasal spray. 